Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients
| Autor: | Susan Lagambina, Gerald L. Weinhouse, Paul Nuccio, Kevin E. Anger, Heather Torbic, Paul M. Szumita |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
ARDS Critical Illness medicine.medical_treatment Comorbidity Nitric Oxide Critical Care and Intensive Care Medicine law.invention Hypoxemia law Administration Inhalation medicine Humans Hypoxia Adverse effect Antihypertensive Agents APACHE Retrospective Studies Mechanical ventilation business.industry Oxygenation Middle Aged Hypoxia (medical) medicine.disease Epoprostenol Respiration Artificial Intensive care unit Bronchodilator Agents Treatment Outcome Respiratory failure Anesthesia Female medicine.symptom business |
| Zdroj: | Journal of Critical Care. 28:844-848 |
| ISSN: | 0883-9441 |
| Popis: | Purpose The purpose of this is to compare efficacy, safety, and cost outcomes in patients who have received either inhaled epoprostenol (iEPO) or inhaled nitric oxide (iNO) for hypoxic respiratory failure. Materials and methods This is a retrospective, single-center analysis of adult, mechanically ventilated patients receiving iNO or iEPO for improvement in oxygenation. Results We evaluated 105 mechanically ventilated patients who received iEPO (52 patients) or iNO (53 patients) between January 2009 and October 2010. Most patients received therapy for acute respiratory distress syndrome (iNO 58.5% vs iEPO 61.5%; P = .84). There was no difference in the change in the partial pressure of arterial O 2 /fraction of inspired O 2 ratio after 1 hour of therapy (20.58 ± 91.54 vs 33.04 ± 36.19 [ P = .36]) in the iNO and iEPO groups, respectively. No difference was observed in duration of therapy ( P = .63), mechanical ventilation ( P = .07), intensive care unit ( P = .67), and hospital lengths of stay ( P = .26) comparing the iNO and iEPO groups. No adverse events were attributed to either therapy. Inhaled nitric oxide was 4.5 to 17 times more expensive than iEPO depending on contract pricing. Conclusions We found no difference in efficacy and safety outcomes when comparing iNO and iEPO in hypoxic, critically ill patients. Inhaled epoprostenol is associated with less drug expenditure than iNO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect